Neurology Central

Why do so many clinical trials for Alzheimer’s fail? New discovery sheds light

Researchers have discovered a vicious feedback loop underlying brain degeneration in Alzheimer’s disease, which may explain why so many drug trials have failed.

The study also identifies a clinically approved drug – fasudil – that could break the vicious cycle and protects against memory loss in animal models of Alzheimer’s.

Overproduction of the protein β-amyloid is strongly linked to development of Alzheimer’s disease but many drugs targeting β-amyloid have failed in clinical trials. β-amyloid attacks and destroys synapses and results in memory problems, dementia and ultimately death.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.